Overview

A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of AMG 623 in Subjects With Systemic Lupus Erythematosus

Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
This study is to evaluate the safety of AMG 623 in subjects with systemic lupus erythematosus. All subjects will receive 4 weekly doses of study drug over a 3 week period, and then will be followed for an additional 28 weeks, for total study duration of 31 weeks.
Phase:
Phase 1
Details
Lead Sponsor:
Amgen